← Back to Search
A Multicenter Phase II Study Of Cisplatin, Pemetrexed, And Bevacizumab In Patients With Advanced Malignant Mesothelioma.
J. Dowell, F. Dunphy, R. Taub, D. Gerber, Likheng Ngov, J. Yan, Y. Xie, H. Kindler
Published 2012 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
INTRODUCTION Malignant mesothelioma (MM) cells express the vascular endothelial growth factor (VEGF) receptor, and VEGF protein expression is detected in a majority of human mesothelioma biopsy specimens. Bevacizumab is a recombinant humanized monoclonal antibody that blocks the binding of VEGF to its receptor. We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM. METHODS Previously untreated MM patients with advanced, unresectable disease received cisplatin (75 mg/m(2)), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg) intravenously every 21 days for a maximum of 6 cycles. Patients with responsive or stable disease received bevacizumab (15 mg/kg) intravenously every 21 days until progression or intolerance. The primary endpoint was progression-free survival rate at 6 months. RESULTS 53 patients were enrolled at 4 centers; 52 were evaluable for this analysis. The progression-free survival rate at 6 months was 56% and the median progression-free survival was 6.9 months (95% confidence interval [CI], 5.3-7.8 months). The partial response rate was 40% and 35% of patients had stable disease. Median overall survival was 14.8 months (95% CI; 10.0-17.0 months). Grade 3/4 toxicities included neutropenia in 11%, hypertension in 6%, and venous thromboembolism in 13% of patients. CONCLUSION This trial evaluating the addition of bevacizumab to cisplatin and pemetrexed in patients with previously untreated, advanced MM failed to meet the primary endpoint of a 33% improvement in the progression-free survival rate at 6 months compared with historical controls treated with cisplatin and pemetrexed alone.
This paper references
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
V. Ranpura (2011)
O-26 Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies
N. Pavlakis (2003)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.
P. Baas (2011)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
SU 5416 in malignant mesothelioma : a University of Chicago phase II consortium study
HL Kindler (2001)
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
S. R. Nalluri (2008)
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
H. Dvorak (2002)
Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.
G. Azzi (2010)
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
J. König (1999)
G. W. Snedecor (1964)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1
Y. Soini (2001)
Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first - line therapy in patients with malignant pleural mesothelioma ( MPM )
GL Ceresoli (2011)
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
J. Thigpen (2011)
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura (2010)
G. W. Snedecor (1980)
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
H. Hurwitz (2011)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
This paper is referenced by
The Immunogenic Effect of Local Radiation Therapy in a Murine Model of Mesothelioma
de la Maza Borja (2015)
The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
E. Pulford (2017)
Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies
K. Lau (2013)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Yusuke Takayama (2016)
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
Mesothelioma treatment: Are we on target? A review
B. Hiddinga (2015)
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
L. Calabrò (2017)
Nintedanib : new treatment for malignant pleural mesothelioma
What can independent research for mesothelioma achieve to treat this orphan disease?
A. Guazzelli (2019)
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
D. Márquez-Medina (2015)
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Y. Tsutani (2018)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
M. Wu (2015)
Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma
K. Mikami (2014)
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Pavel A. Levin (2017)
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.
S. Kubo (2015)
New directions in mesothelioma treatment
Anna K. Nowak (2015)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma
P. L. Chia (2016)
Current Therapies for Malignant Mesothelioma
A. Shukla (2014)
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
Mesothelioma: An Evidence-Based Review
J. Goudreault (2013)
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
Y. Tada (2015)
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Modern management of malignant pleural mesothelioma
S. Patel (2016)
Current issues in malignant pleural mesothelioma evaluation and management.
J. Ai (2014)
The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
O. Lauk (2020)
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
M. Mencoboni (2017)See more